CLINICAL AND PHYSIOLOGICAL CHARACTERISTICS OF SPINAL ANESTHESIA WITH QUANADEX DURING CESAREAN SECTION

                                                                                                                                                                          ABSTRACT

The purpose of this research was to study Quanadex as an adjuvant to Longocain Heavy 0.5% solution for injections for clinical and physiological characteristics, efficacy and neonatal outcomes during cesarean section. A prospective double-blind randomized controlled clinical trial was conducted in 189 women, without severe extragenital pathology, with ASA II physical status. Group I consisted of pregnant women who were intrathecally injected with Longocain Heavy 0.5% hyperbaric solution, Group II women were injected with Longocain Heavy 0.5% hyperbaric solution in combination with 6 mcg Quanadex. The intravenous infusion of balanced polyelectrolyte hyperosmolar solution of Reosorbilact in a volume of 3–5 ml/kg preceded the spinal injection. Central hemodynamics, ANS, interleukin-6 were assessed, and newborns were evaluated on the Apgar scale at the 1st and 5th minutes. Studies have shown that the use of Quanadex, a highly selective α₂-adrenergic receptor agonist, as an adjuvant to a 0.5% solution of Longocaine Heavy accelerates the onset of sensory-motor blockade, provides a longer sensory-motor block without significant effect on hemodynamics and ANS parameters, significantly reduces anesthetic and surgical stress and does not have a depressive effect on newborns in neonatal period of adaptation.